Rob Davis, Merck CEO

Mer­ck’s Keytru­da nears $21B in sales, dou­bles down on com­bo tri­als

Mer­ck’s can­cer im­munother­a­py Keytru­da notched sales of $20.9 bil­lion in 2022, ce­ment­ing its sta­tus as one of the world’s top-sell­ing drugs. How­ev­er, it’s far from rest­ing on that ac­com­plish­ment.

Mer­ck ex­ec­u­tives tout­ed nine on­go­ing tri­als in its an­nu­al earn­ings call on Thurs­day, in­clud­ing five stud­ies in Phase III, for Keytru­da (pem­brolizum­ab) in com­bi­na­tion with oth­er im­muno-on­col­o­gy drugs. The tri­als in­clude com­bi­na­tions with Mer­ck’s own de­vel­op­ments as well as oth­er phar­ma com­pa­nies’ can­di­dates, in­clud­ing its melanoma col­lab­o­ra­tion with Mod­er­na and its mR­NA tech­nol­o­gy plus Keytru­da, aimed at cre­at­ing a per­son­al­ized vac­cine treat­ment to re­duce the risk of can­cer re­cur­rence or death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.